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Summary.-A group of 12 children with advanced neuroblastoma (7 Stage IV and
5 Stage III), selected by their initial response to chemotherapy with pulsed cyclo-
phosphamide/vincristine/Adriamycin (CVA), were given consolidation therapy
with high-dose melphalan (140 mg/M2) and then surgical removal ofresidual disease.
Twenty-two high-dose melphalan procedures were combined with autologous
marrow grafting to offset myelotoxicity and were well tolerated. In each of 2 addi-
tional children, procedures carried out without marrow autografting led to serious
marrow and mucosal toxicity. There were no treatment-related deaths. In 7/11
patients with evaluable computerized tomographic (CT) scans there was a decrease
in maximum diameter of the primary tumour after melphalan. Complete response
was achieved in 6 patients, of whom 3 are well and have no evidence of disease at 35,
33 and 18 months from completion of all treatment; however, although survival
(median23 months) of all 12 autografted patients is longer than that of28 comparable
childrentreated between 1970-77withconventionalchemotherapy (median14months)
the difference is not statistically significant. High-dose melphalan is a safe and
tolarable treatment in children when combined with autologous marrow grafting,
but further study is required to determine whether the procedure can improve
prognosis for patients with advanced neuroblastoma.
ADVANCED NEUROBLASTOMA is one of
the most lethal ofall childhood neoplasms.
The 2-year survival for children with
Stage IV (Evans et al., 1971) disease
(excluding IVs patients) diagnosed and
treated by us with conventional chemo-
therapy, radiotherapy and surgery is
10-15% (Ninane et al., 1981); and this
dismal experience is shared by others
(Gasparini et al., 1974; Finklestein et al.,
1979; Helson et al., 1979). For stage III
tumours, reported 2-year survival figures
vary more, but in no series exceed 50%;
our own experience is that Stage III
patients with unresectable primary dis-
ease fare just as badly as those with Stage
IV disease (Ninane et al., 1981).
Between 1977 and 1979, in an attempt
to improve the prognosis for children with
advanced neuroblastoma, we studied the
effect of high-dose melphalan (HDM)
chemotherapy in 14 patients with Stage
III or IV disease who had undergone
"induction" chemotherapy with cyclo-
phosphamide, vincristine and Adriamycin
(CVA). We chose this approach because of
previous experience of responses to HDM
in patients with another neural-crest
tumour, malignant melanoma (McElwain
et al., 1979a) and because its major side-
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effect, myelotoxicity, could be overcome
by autologous marrow grafting (McElwain
et al., 1979b). The short plasma half-life of
melphalan permits the return of anti-
coagulated, non-cryopreserved marrow to
the patient 8 h after harvesting (Mc-
Elwain et al., 1979b) thus eliminating the
technical problems of long-term marrow
storage (Abrams et al., 1980). A pre-
requisite for marrow autografting, carried
our in 12 patients, was that the child's
marrow was morphologically clear of
tumour cells at the time of harvesting.
Two patients, whose marrows still con-
tained tumour cells despite CVA therapy,
were also given HDM, butwithout marrow
support.
In this paper, we assess the practic-
ability and value of this treatment
approach in 14 patients with advanced
neuroblastoma. Some of our results have
already been published in preliminary
form (McElwain et al., 1979a).
PATIENTS AND METHODS
Diagnosis and staging.-In each of the
patients (Table I), a diagnosis of neuroblas-
toma was established by either (a) tissue
biopsy or (b) significantly elevated 24h
urinary vanillyl-mandelic acid (VMA) excre-
tion and cytological evidence of marrow
infiltration by tumour cells. Surgery was
eventually performed in 10 patients and
yielded histological confirmation in 9 ofthem.
Staging investigations included full blood
count, chest X-rays, IVU, skeletal survey,
liver and bone radioisotope scans, and
marrow aspirates and/or trephine biopsies
from at least 2 sites. Computerized tomo-
graphy (CT) and ultrasound examinations
were used serially to assess the size of the
primary tumours. In 5 patients, lymph nodes
were involved; however, because most of the
primary tumours were abdominal and since
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FIG. 1.-Treatment schema: Some patients
(see Table I) received more than 6 courses
of cyclophosphamide/vincristine/adriamy-
cin (CVA). Not all patients underwent
surgery and radiotherapy (see text).
* mg/M2; MAG =autologous bone marrow
graft; S=surgery; B=biopsy; RT=
radiotherapy.
TABLE I.-Clinical details of 14patients atpresentation, details ofinduction chemotherapy
("CVA"-see Fig. 1) and marrow status prior to HDM
Stage
III
IV
IV
IV
IV
IV
IV
III
III
III
IV
III
IV
IV
Disease sites at presentation* No. of
Ir A courses
Site of Lymph of
primary§ nodes Liver Bone Marrow Other CVA
T/A Pleura 12
A - - + + Dura 6
A + - - - - 12
? - + - - - 8
A + - + + Scalp 7
T/A + - + + - 8
A + - - + Pleura 6t
T/A - - - - Pleura 6:
A - - - - - 9
A - - - - - 6
A - + + + - 7
A - - - - - 8
A - + + + Dura? 6
A + - + + - 6
Marrow
status
after
CVA
?=primary unknown.
* + =involved by tumour.
- =no measurable involvement by tumour.
t =patient had 6 additional pulses of cyclophosphamide during induction treatment.
I=patient had induction therapy with Adriamycin alone.
§ A =abdominal; T =thorax. Pleural involvement in 2 cases was direct extension of primary but in the
3rd was judged to be metastatic.
Age
at
diagnosis
(years)
2
4
3
16
4
2
9
13
2
2
5
8/12
5
9
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
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the rate ofinitial laparotomy was low, this is
almost certainly an underestimate. All but
patient 9 excreted abnormally high levels of
urinary VMA.
Treatment schema.-This is shown in Fig. 1.
To be considered for autologous marrow
grafting, we required that patients' marrow
aspirates and/or trephine biopsies, from at
least 2 sites, were morphologically clear of
neuroblastoma. Ofthe 12 eligible children, 11
had received 6-12 (median 8) courses of CVA
(Table I) prior to HDM, whilst a single
patient with Stage III disease had received
only Adriamycin, but was considered eligible
for the study. Patients 13 and 14, whose
marrows showed persistent infiltration by
tumour after 6 courses ofCVA, were ineligible
for autografting.
Procedure for high-dose melphalan (HDM).
-Patients for HDM were completely re-
staged using the investigations listed above.
Full blood counts and renal function were
confirmed as normal. Oral non-absorbable
antibiotics ('FRACON', [Storring et al., 1977]
or amphotericin/neomycin) were prescribed.
Under general anaesthesia, a bladder catheter
and a central venous line orHickman catheter
were inserted just before heparinization of
the patient, and marrow was harvested as
previously described for adults (McElwain
et al., 1979a; Thomas et al., 1975). One-2 ml
marrow aspirates were taken into 20ml
heparinized syringes from multiple sites in
both anterior and posterior iliac crests and, in
one case, the tibiae. Median yields of nuc-
leated marrow cells were, for the first auto-
graft, 41 x 108/kg (range 1-8-33-0 x 108) and,
for the second, 4-6 x 108/kg (range 2-2-7-7 x
108/kg). Whole blood, equal involumetothat
ofthe marrow aspirate, was transfused during
the procedure. No protamine sulphate was
given. The marrow was stored, at 4°C, in a
plastic transfer pack. On return to the ward,
patients were nursed in cubicles using a
simple "reverse isolation" technique with
hand-washing and gowning. One parent
"lived in" with each child and carried out
many of the simpler nursing procedures.
After recovery from anaesthesia, a few
patients required a single dose of morphine
for discomfort from sites of marrow aspira-
tion. Melphalan (140 mg/i.v. as bolus) was
given through the central venous line 1-2 h
after recovery from anaesthesia; a brisk
diuresis (6-8 ml urine/kg/h) was then induced
using frusemide (2 mg/kg) and normal saline
with added potassium. Eight hours after
melphalan the marrow was returned via the
central venous line. Twenty-four hours after
melphalan, the bladder catheter was removed
and the diuresis discontinued, but most
children required i.v. fluids for a further
24-48 h because of nausea and anorexia.
Appropriate supportive care was given
during the 2-3 weeks of pancytopenia follow-
ing HDM. After 4-6 weeks at home and
recovery of their blood count, 10 patients
returned to hospital for a second HDM
procedure. Patient 8 declined further chemo-
therapy and abnormal liver function tests
post-HDM were considered a contra-indica-
tion to a second procedure in patient 4.
Further treatment and follow-up.-No fur-
ther chemotherapy was given, but, 6-10
weeks after HDM, 9 patients underwent
exploratory leparotomy in an attempt to
remove residual disease or, at least, obtain
samples for histology. Radiotherapy was
given to 2 patients with localized residual
abdominal disease after surgery: patient 9
received a dose (25 Gy in 10 fractions over 29
days) considered technically and therapeutic-
ally adequate, but in patient 10 a final dose
of 15 Gy (considered suboptimal) was
achieved only after several interruptions
because of thrombocytopenia.
All treatment was concluded between 9
and 15 months (median 12) from diagnosis.
Subsequent follow-up was with regular
clinical examination and VMA estimations,
4-monthly marrow examinations and abdom-
inal ultrasound and bone scans or skeletal
surveys when indicated.
RESULTS OF TREATMENT
Tumour response (Table II)
Of the 12 patients who, just before
HDM, had localized disease only, 11 had
evaluable serial CT scans, and 7 showed
some shrinkage of maximum tumour
diameter as a result of the treatment (e.g.
Fig. 2) "Complete response" (CR) status
(defined as: no clinical or imaging evi-
dence of primary or secondary tumour,
normal marrow aspirates and/or trephines
and normal urinary VMA) was achieved in
6 ofthese 12 patients, but in patients 1, 2,
5 and 11, only after surgical excision of
residual disease. Six children never
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TABLE II.-Disease response to HDM and to all treatment, sites of relapse and outcome
Measurable
disease
prior to HDM
Measurable
disease
after HDM
Measurable
disease
after all R.
Site of
relapse
1 P P4 CR -
2 P P CR
3 p p p P, LN
4 LN, VMA VMA VMA H, BM
5 P, VMA P4 CR?* BM
6 P P P P, BM
7 CR CR CR pleura, BM
8 P P P
9 P Pt P4 H
10 P P p4, P, lung
11 P, ?LN P CR B, BM
12 P, VMA CR (P4) CR _
13 P, H, B, BM, VMA P, H, B, BM* P, H, B, BM, VMA Progressive
disease
14 P, BM, VMA P, BM, VMA P, BM, VMA Progressive
disease
Abbreviations: P =primary tumour VMA
4, = some decrease in maximum diameter
of P via HDM surgery B
LN =lymph nodes BM
H =liver *
NED = no evidence of tumour
Outcome
_t I
Months
from
Status initial R.
NED
NED
Died
Died
Died
Died
Died
Died
Died
Died
Died
NED
Died
Died
45
43
18
31
13
32
23
41
11
20
17
26
12
29
= increased urinary
VMA excretion
=bone
= marrow
=VMA not estimated
FIG. 2.-CT scans of the abdomen demonstrating left adrenal primary tumour of patient 10 immedi-
ately before (a) and after (b) 2 courses of HDM. Over 50% shrinkage of maximum diameter and
increased calcification are shown.
achieved CR. Patients 3 and 8 had residual
unresectable gross disease, whilst in
patients 9 and 10 microscopic disease
remained after "second-look surgery" and
was treated with radiotherapy. In patient
6 a residual primary para-spinal tumour,
detectable by CT scanning, could not be
located at laparotomy, whilst, for patient
4, persistently highurinary VMA excretion
was the only evidence of residual disease.
Neither child (patients 13 and 14) with
metastatic disease at the time of HDM
showed objective response to this treat-
ment.
Piatient
I
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FIG. 3.-Progress chart for patient 10. During induction blood counts were only performed just
before each pulse of CVA. Chemotherapy doses are in mg/M2, L-PAM=melphalan, t =elevated
urinary VMA excretion, sl =slightly elevated VMA excretion, BT =red cell transfusion, =child
died.
% Survival
Months from diagnosis
FiG. 4.-Survival after initial response to
treatment; comparison of 12 HDM/
autograft patients ---] (this series)
with 28 patients [ ] (Ninane et al.,
1981) with similar initial response to CVA
or CV who continued treatment with this
chemotherapy, ±radiotherapy ± surgery to
local disease. 0 denotes disease-free
survivor.
Survival and relapse (Fig. 2, Table II)
Of the 12 children receiving autografts
3 (patients 1, 2 and 12) remain alive, with-
out evidence ofneuroblastoma, 35, 33 and
18 months from the end of all treatment.
All 3 had achieved CR, one after chemo-
therapy alone and 2 after chemotherapy
and surgery. The 9 other children have
died of disseminated tumour recurrence;
in 3 there was simultaneous recurrent
disease at the primary site. Both non-
autografted children experienced relief of
symptoms after HDM; one survived for 8
months and the other, with the help of
alternative chemotherapy, for 22 months
before dying of metastatic tumour.
Complications
A total of 24 HDM procedures were
carried out in 14 patients, 22 with auto-
logous marrow support. There were no
complications from heparin anticoagula-
tion even without protamine reversal.
Administration of melphalan through a
central venous line eliminated the severe
local discomfort of administration by
peripheral vein. No hypotensive episodes,
previously noted by us in adults (Mc-
Elwain et al., 1979a) were seen in these
children, possibly because careful volume-
for-volume whole-blood replacemnent of
aspirated marrow was carried out during
.; :_
J.
*:.
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the procedure. Recovery of total leuco-
cyte counts to 0 x 109/1, of neutrophil
counts to 0.8 x 109/1 and of platelet
counts to 80 x 109/1 occurred at medians
of 9-5 (range 3-21), 16 (9-28) and 27-5
(9-36) days respectively after the first
HDM treatment, and at medians of 12
(6-20), 25-5 (11-36) and 37-5 (28-indefi-
nite-see Discussion) days after the sec-
ond. These figures are comparable to those
previously reported (McElwain et al.,
1979a, b) for adults after HDM.
All children received platelet support
at counts below 20 x 109/1; only one in-
stance of overt bleeding was detected, and
responded promptly to further platelet
transfusion. After 2 courses of HDM, 3
patients, each of whom ultimately suc-
cumbed to tumour, had persistent throm-
bocytopenia stabilizing at 50-100 x 109/1
(see Fig. 4).
Since total nucleated cell yields and
marrow volumes were similar for both
harvests in the 10 patients who under-
went 2 autografts, this incomplete haemo-
poietic reconstitution was not apparently
related to a reduced marrow "dose" at the
second procedure. The 2 patients without
autografts showed slower blood-count
recovery than the grafted patients; con-
sequently, they spent longer in hospital
(median 22-5 days for grafted and 30 days
for non-grafted patients) and experienced
the only 2 serious infective complications
in the entire series. One child suffered
severe stomatitis, with secondary thrush
and bleeding, and severe diarrhoea; the
second developed an E. coli septicaemia,
the only documented systemic infection
in the entire group. Both patients re-
covered, but only after receiving white-
cell transfusions as well as antibiotics. All
other patients received empirical broad-
spectrum antibiotic therapy after develop-
ment ofpyrexia of unknown origin whilst
neutropenic, but no bacterial pathogens
were isolated. No graft-versus-host disease
was recognized.
Serum IgG, IgM and IgA were normal
throughout treatment of 2 patients, but
there was a fall in lymphocyte response to
PHA and loss of skin reactivity to can-
didin just after HDM. Unfortunately,
neither patient survived long enough to
permit retesting at a longer interval after
melphalan. Serious viral or fungal infec-
tions, however, did not occur; one child
developed shingles and another measles
22 months after their last chemotherapy
but recovered without complications.
Other complications of treatment were
rare. One patient developed hyper-
uricaemia (1 1 mM) 3 days after his first
HDM treatment; since this episode co-
incided with a rapid decrease in size ofthe
primary tumour, it was presumed to be
the consequence ofcelllysis, aphenomenon
we have never encountered in children
with neuroblastoma receiving conven-
tional chemotherapy. Serial electrolyte
estimations after HDM were normal, as
were liver-function tests, except in one
child whose SGOT and SGPT were
moderately raised, without jaundice, for
6-8 weeks. Most children lost > 10% of
their body weight as a result of each
HDM treatment but quickly regained it
after discharge from hospital and before
a second procedure.
DISCUSSION
In designing this protocol we had in
mind the characteristics of relapse in
patients with Stage III and IV neuro-
blastoma. After partial response to con-
ventional treatment, "recurrence" is gen-
erally local within a median time of about
6 months, whilst after CR tumour recur-
rence characteristically occurs at meta-
static sites after a median of 15 months
(Ninane et al., 1981). Surgical resection
of disease after conventional chemo-
therapy, with or without radiotherapy,
does not appear to improve survival
(Finklestein et al., 1979). Sequential
segmental whole-body irradiation did not
improve duration of first response in one
reported series (Green et al., 1976) and
although single-dose 10 Gy total-body
irradiation followed by allogeneic marrow
grafting from an HL-A compatible sibling
requiresfurtherinvestigation, earlyresults
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are not encouraging (Klemperer et al.,
1976; Evans & d'Angio, personal com-
munication: McElwain et al., personal
communication). We therefore decided
to explore the possibility that high-dose
chemotherapy, by eliminating metastases
and shrinking primary disease, might lead
to improved CR rate and outcome. Of
drugs conventionally active against neuro-
blastoma, only some alkylating agents
(Thurman et al., 1964) lack predictable
dose-related specific organ toxicity. We
decided against the use of cyclophospha-
mide because of (a) the risk of cystitis
(Phillips et al., 1961) and cardiomyopathy
(Buchner et al., 1972), (b) the need, after
CVA induction therapy, to expose the
tumours to a "new" agent in order to
side-step the problem of emerging drug
resistance and (c) the reported failure of
high-dose cyclophosphamide to improve
the prognosis in advanced neuroblastoma
(Helson, 1979; Nitschke et al., 1979a).
Encouraged by response rates to Pepti-
chemio (de Bernardi et al., 1978) up to
9200, we decided to use the closely related
alkylating agent melphalan for high-dose
consolidation. The only previous use of
melphalan in neuroblastoma was not
encouraging, but in that study (Fernbach
et al., 1968) and in contrast to our own
plans, a low-dose schedule of oral adminis-
tration was used. Our protocol was so
designed that HDM would be introduced
at a time of estimated minimum tumour
burden; we measured its effect by serial
CT scanning, laparotomy after treatment
and crude survival.
Marrow harvesting, even in the smallest
children, presented no particular prob-
lems, though in one 2-year-old tibial
marrow was aspirated to reach an ade-
quate cell dose. Of considerable import-
ance was the fact that none of these
children had previously received pelvic
irradiation, which greatly reduces the
chance of an adequate cell yield. The
mean dose was similar to that used in
adults (McElwain et al., 1979a). HDM was
well tolerated in all patients who received
autologous marrow grafts. No life-
threatening episodes, apart from one
septicaemia, were encountered in the
entire series, but our experience of serious
complications with the 2 non-autografted
children, their marrows admittedly com-
promised by tumour infiltration, together
with our previous findings in adults
(McElwain et al., 1979b) convince us that
marrow autografting significantly reduces
the morbidity from HDM therapy. Oral
non-absorbable antibiotics and nystatin
were administered, but compliance was
poor because of mucositis and nausea. We
now use the more palatable combination
ofCotrimoxazole and nystatin for patients
undergoing HDM therapy. Energetic
diuresis was used after melphalan, because
2 adult patients, early in our experience
(McElwainetal., 1979a) developed compro-
mised renal function post-HDM. We now
have evidence that diuresis is unnecessary.
Weight loss of > 10% in each of our
patients might have been prevented by
early i.v. feeding: we now invariably start
parenteral feeding immediately after
HDM.
The 14 children reported here represent
less than two-thirds of the 22 patients
referred to our 3 hospitals with a diagnosis
of Stage III or IV neuroblastoma during
the 2 years ofthe study. Ofthe remainder,
6 were considered ineligible for HDM
because of non-response to initial (CVA)
chemotherapy, 1 because of pre-existing
brain damage, and the last because of a
chemotherapy-induced malabsorption syn-
drome. That our patients are a "selected"
group thus primarily reflects the failure of
CVA as an induction regimen.
Three children (Stage III patients 1
and 12, Stage IV patient 2) are well and
free of evidence of disease between 11-3
years from the end of treatment. The
survival of the 12 patients who had
localized disease just before :HDM (median
23 months) is, however, not significantly
different (Logrank test P= 0 76) from that
of previous patients achieving clinical CR
by conventional therapy (median 14
months-Ninane et al., 1981). Moreover,
neither child with overt metastases at the
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time ofHDM showed objective response to
the treatment. However, since all therapy
was completed 9-15 months after diag-
nosis, the quality of the subsequent lives
of children receiving HDM was substanti-
ally better than those treated prior to
1977.
In 8/9 relapsing patients, disease re-
turned at metastatic sites; however, there
was simultaneous local recurrence in 3 of
these children, each of whom had had
incomplete surgical resection, and one had
a suboptimal radiation dose as well. We
therefore feel that a more aggressive ap-
proach towards residual localized disease,
using both surgery and high-dose age-
adjusted radiation therapy, even in the
face of a falling blood count, would have
been justified. There are several possible
explanations for relapse at distant sites.
The most likely is that HDM failed to
destroy occult metastases; alternatively,
the "new" metastases might represent
re-seeding of tumour cells either present
in the reinfused autologous marrow or
from the primary site. The pattern and
timing of reappearance of metastases does
not permit distinction between these
possibilities, of which the third seems
unlikely in the 5 cases in which secondary
disease recurred without evidence of local
relapse.
We conclude that HDM is a safe and
tolerable procedure in children when
combinedwith autologousmarrowgrafting,
expert nursing and close parental support
in specialized units. Because of encourag-
ing results of high-dose chemotherapy,
including melphalan, in other forms of
cancer (Ziegler et al., 1977, Cornbleet et al.,
1981) and despite the disappointing overall
results in this series of children, we con-
tinue to use HDM consolidation in patients
with advanced neuroblastoma. We now
use more intensive induction therapy,
including cis-Platinum and VM-26, agents
which have been shown to be active both
individually (Rivera et al., 1977, Nitschke
et al., 1979b) and together (Hayes et al.,
1981) in neuroblastoma, and pay particu-
lar attention to the radiation and surgical
therapy of residual primary disease.
Finally, we are exploring the possibility
that monoclonal antibodies, knownto bind
to human neuroblastoma cells (Kemshead
et al., 1981) might be used to "clean up"
autologous marrow before reinfusion.
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